Difference between revisions of "Team:Heidelberg/CRISPR"
| Line 17: | Line 17: | ||
{{Heidelberg/templateus/Contentsection| | {{Heidelberg/templateus/Contentsection| | ||
{{#tag:html| | {{#tag:html| | ||
| − | <h1 id="id"> | + | <h1 id="id">Introduction</h1> |
| − | Many of nowadays most threatening diseases are caused by mutations, epi mutations or other changes in the genome. Although medical research was always supplied by innovations in biological research and especially by the field of genetics, which developed rapidly during the last decades, there are still many diseases that cannot be cured or even treated adequately. Recently, the CRISPR/Cas9 technology raised hope of the scientific community to treat genetic disorders. This technique has dramatically simplified the way genomes can be manipulated. However, there are still many challenges to be surpassed. Cas9 and related endonucleases are enzymes, which are able to induce double strand breaks in the genome. Importantly, they only cut specific sequences to which they are guided by a so called guideRNA (gRNA). A gRNA consists of a 3' scaffold, which is obligatory for the binding of the Cas9 enzyme, a protospacer sequence, and 20 nucleotides at the 5'-end that are complementary to the target DNA. Once the Cas9 endonuclease binds to the DNA, it cleaves three nucleotides upstream of the protospacer 3'-end. This system allows to target virtually any position in any genome. However, there is one major restriction in the applicability of this system. Only sequences can be targeted that carry a specific recognition motif directly downstream of the spacer, the protospacer adjacent motif (PAM). In case of Cas9, the consensus PAM is NGG <x-ref>Jinek2012</-ref>. The past few years, much effort has been put into the development of the CRISPR/Cas9 technique. In order to create even more sophisticated systems, many attempts have been made to modify the CRISPR-associated (Cas) endonucleases, for example the development of a catalytically inactive dCas9 <x-ref>RN141</-ref> or nickases <x-ref>Mali2013x</-ref>. | + | Many of nowadays most threatening diseases are caused by mutations, epi mutations or other changes in the genome. Although medical research was always supplied by innovations in biological research and especially by the field of genetics, which developed rapidly during the last decades, there are still many diseases that cannot be cured or even treated adequately. Recently, the CRISPR/Cas9 technology raised hope of the scientific community to treat genetic disorders. This technique has dramatically simplified the way genomes can be manipulated. However, there are still many challenges to be surpassed. Cas9 and related endonucleases are enzymes, which are able to induce double strand breaks in the genome. Importantly, they only cut specific sequences to which they are guided by a so called guideRNA (gRNA). A gRNA consists of a 3' scaffold, which is obligatory for the binding of the Cas9 enzyme, a protospacer sequence, and 20 nucleotides at the 5'-end that are complementary to the target DNA. Once the Cas9 endonuclease binds to the DNA, it cleaves three nucleotides upstream of the protospacer 3'-end. This system allows to target virtually any position in any genome. However, there is one major restriction in the applicability of this system. Only sequences can be targeted that carry a specific recognition motif directly downstream of the spacer, the protospacer adjacent motif (PAM). In case of Cas9, the consensus PAM is NGG <x-ref>Jinek2012</x-ref>. The past few years, much effort has been put into the development of the CRISPR/Cas9 technique. In order to create even more sophisticated systems, many attempts have been made to modify the CRISPR-associated (Cas) endonucleases, for example the development of a catalytically inactive dCas9 <x-ref>RN141</x-ref> or nickases <x-ref>Mali2013x</x-ref>. |
Attempts to change endonuclease activity by directed evolution have already been made <xref> | Attempts to change endonuclease activity by directed evolution have already been made <xref> | ||
| − | JM_5</-ref><x-ref>Gao2017</-ref>. We wanted to show that *in vivo* directed evolution of endonucleases is possible as well. This approach would overcome the limitations of the evolution based on rationalities and would offer new tools for the genome engineering research area. | + | JM_5</-ref><x-ref>Gao2017</x-ref>. We wanted to show that *in vivo* directed evolution of endonucleases is possible as well. This approach would overcome the limitations of the evolution based on rationalities and would offer new tools for the genome engineering research area. |
<h1 id="id">The Idea</h1> | <h1 id="id">The Idea</h1> | ||
| Line 31: | Line 31: | ||
All parts, which were necessary for the assembly of Accessory Plasmids were generated by PCR with the respective homology regions in the extensions. Subsequently, they were assembled by CPEC. All APs carry a bicistronic operon for the expression of geneIII and luxAB as luminescent reporter downstream of the promoter, described above. An expression cassette with the required gRNA under the control of a constitutive promoter is located on the same plasmid. APs varying in the copy number of their origins of replication and the strength of the RBS upstream of geneIII were cloned %%tabref:<1>; %%tab:1; Plasmids, that were cloned for the evolution of PAM specificity, the plasmid names, and the functional parts they consist of are shown. | All parts, which were necessary for the assembly of Accessory Plasmids were generated by PCR with the respective homology regions in the extensions. Subsequently, they were assembled by CPEC. All APs carry a bicistronic operon for the expression of geneIII and luxAB as luminescent reporter downstream of the promoter, described above. An expression cassette with the required gRNA under the control of a constitutive promoter is located on the same plasmid. APs varying in the copy number of their origins of replication and the strength of the RBS upstream of geneIII were cloned %%tabref:<1>; %%tab:1; Plasmids, that were cloned for the evolution of PAM specificity, the plasmid names, and the functional parts they consist of are shown. | ||
| + | |||
| + | {{Heidelberg/templateus/Imagebox| | ||
| + | https://static.igem.org/mediawiki/2017/6/6a/T--Heidelberg--Team_Heidelberg_2017_pampace4.jpeg| | ||
| + | Title| | ||
| + | Subtitle| | ||
| + | pos = left | ||
| + | }} | ||
General rules: | General rules: | ||
Revision as of 13:40, 31 October 2017
CRISPR Cas9
PACE for the Evolution of Endonucleases
Introduction
Many of nowadays most threatening diseases are caused by mutations, epi mutations or other changes in the genome. Although medical research was always supplied by innovations in biological research and especially by the field of genetics, which developed rapidly during the last decades, there are still many diseases that cannot be cured or even treated adequately. Recently, the CRISPR/Cas9 technology raised hope of the scientific community to treat genetic disorders. This technique has dramatically simplified the way genomes can be manipulated. However, there are still many challenges to be surpassed. Cas9 and related endonucleases are enzymes, which are able to induce double strand breaks in the genome. Importantly, they only cut specific sequences to which they are guided by a so called guideRNA (gRNA). A gRNA consists of a 3' scaffold, which is obligatory for the binding of the Cas9 enzyme, a protospacer sequence, and 20 nucleotides at the 5'-end that are complementary to the target DNA. Once the Cas9 endonuclease binds to the DNA, it cleaves three nucleotides upstream of the protospacer 3'-end. This system allows to target virtually any position in any genome. However, there is one major restriction in the applicability of this system. Only sequences can be targeted that carry a specific recognition motif directly downstream of the spacer, the protospacer adjacent motif (PAM). In case of Cas9, the consensus PAM is NGGThe Idea
To prove our hypothesis, we planned a circuit for the directed evolution of PAM specificity of Cas9. We chose a system for the transcription activation, which contains a dCas9 fused to a RNA polymerase Ω subunit (rpoZ). In our scenario, the nuclease targets a region upstream of a minimal promoter. In case the dCas9 is able to bind the DNA, the fused rpoZ recruits the transcription machinery and geneIII is expressed. By changing the PAM sequence or generating PAM libraries, it is possible to induce a selection pressure on the randomly mutating protein. As a result, proteins with a weaker PAM specificity evolve, which can be used, no matter if the NGG motif is present exactly at the desired position. Of course, this first circuit was designed according to our cloning standard by Gibson assembly.Design of the Accessory Plasmids
All parts, which were necessary for the assembly of Accessory Plasmids were generated by PCR with the respective homology regions in the extensions. Subsequently, they were assembled by CPEC. All APs carry a bicistronic operon for the expression of geneIII and luxAB as luminescent reporter downstream of the promoter, described above. An expression cassette with the required gRNA under the control of a constitutive promoter is located on the same plasmid. APs varying in the copy number of their origins of replication and the strength of the RBS upstream of geneIII were cloned %%tabref:<1>; %%tab:1; Plasmids, that were cloned for the evolution of PAM specificity, the plasmid names, and the functional parts they consist of are shown.
Title
Subtitle
Header
headers can be written as follows:Large header
or in smaller:Smaller Header
this is bold text this produces a line breakThis text is italic Referencing works . Links to other pages work like this. Images can be embedded over the half page:
Title
Subtitle
Title
Subtitle
Title Subtitle
html table
